Jerry Polesel1, Carlo Furlan2, Silvia Birri3, Vittorio Giacomarra4, Emanuela Vaccher5, Giuseppe Grando4, Carlo Gobitti2, Federico Navarria2, Ornella Schioppa5, Emilio Minatel2, Ettore Bidoli3, Luigi Barzan6, Giovanni Franchin2. 1. Unit of Cancer Epidemiology, CRO Aviano National Cancer Institute, via Gallini 2, 33081 Aviano (PN), Italy. Electronic address: polesel@cro.it. 2. Unit of Radiotherapy, CRO Aviano National Cancer Institute, via Gallini 2, 33081 Aviano (PN), Italy. 3. Unit of Cancer Epidemiology, CRO Aviano National Cancer Institute, via Gallini 2, 33081 Aviano (PN), Italy. 4. Unit of Otorhinolaryngology, Santa Maria degli Angeli General Hospital, via Montereale 24, 33170 Pordenone (PN), Italy. 5. Unit of Medical Oncology, CRO Aviano National Cancer Institute, via Gallini 2, 33081 Aviano (PN), Italy. 6. Unit of Surgical Oncology, CRO Aviano National Cancer Institute, via Gallini 2, 33081 Aviano (PN), Italy.
Abstract
OBJECTIVES: To evaluate the impact of time to treatment initiation (TTI) on overall survival in patients with head-and-neck squamous cell carcinoma (HNSCC). MATERIALS AND METHODS: In the period 2003-2009, 1616 HNSCC patients were diagnosed in Friuli Venezia Giulia Region, Northeastern Italy, including 462 oral, 346 oropharyngeal, 212 hypopharyngeal, and 596 laryngeal cancers. Clinical information, including date and type of first treatment, and follow-up were retrieved from the regional Cancer Registry and a population-based health database collecting comprehensive health information on people living in the Region. Multivariate hazard ratio (HR) and confidence intervals (CI) were calculated through Cox model. RESULTS: Overall, the median TTI was 28days, (Q1-Q3: 13-45days), but significant variations emerged according to anatomical site, cancer stage, treatment approach, and care transition to specialized centers. Five-year overall survival decreased with increasing treatment delay from 62% for TTI<30days to 39% for TTI≥90days (p<0.01). HR of death was 1.13 (95% CI: 0.92-1.39) for TTI between 45-89days, and 1.47 (1.05-2.05) for TTI≥90days. The association between TTI and poor prognosis was stronger for laryngeal cancers and early-stage HNSCCs. Further, care transition from community hospitals to specialized centers was associated to a better prognosis (HR=0.73; 95% CI: 0.60-0.88). CONCLUSION: Our study findings suggest that HNSCC patients treated within 45days from diagnosis have increased survival probabilities and that early-stage patients suffered the most from treatment delay. Furthermore, care transition to specialized centers -though competitive to timely treatment- improves survival by providing the most innovative technologies and treatment approaches.
OBJECTIVES: To evaluate the impact of time to treatment initiation (TTI) on overall survival in patients with head-and-neck squamous cell carcinoma (HNSCC). MATERIALS AND METHODS: In the period 2003-2009, 1616 HNSCC patients were diagnosed in Friuli Venezia Giulia Region, Northeastern Italy, including 462 oral, 346 oropharyngeal, 212 hypopharyngeal, and 596 laryngeal cancers. Clinical information, including date and type of first treatment, and follow-up were retrieved from the regional Cancer Registry and a population-based health database collecting comprehensive health information on people living in the Region. Multivariate hazard ratio (HR) and confidence intervals (CI) were calculated through Cox model. RESULTS: Overall, the median TTI was 28days, (Q1-Q3: 13-45days), but significant variations emerged according to anatomical site, cancer stage, treatment approach, and care transition to specialized centers. Five-year overall survival decreased with increasing treatment delay from 62% for TTI<30days to 39% for TTI≥90days (p<0.01). HR of death was 1.13 (95% CI: 0.92-1.39) for TTI between 45-89days, and 1.47 (1.05-2.05) for TTI≥90days. The association between TTI and poor prognosis was stronger for laryngeal cancers and early-stage HNSCCs. Further, care transition from community hospitals to specialized centers was associated to a better prognosis (HR=0.73; 95% CI: 0.60-0.88). CONCLUSION: Our study findings suggest that HNSCC patients treated within 45days from diagnosis have increased survival probabilities and that early-stage patients suffered the most from treatment delay. Furthermore, care transition to specialized centers -though competitive to timely treatment- improves survival by providing the most innovative technologies and treatment approaches.
Authors: Tyler A Janz; Joanne Kim; Elizabeth G Hill; Katherine Sterba; Graham Warren; Anand K Sharma; Terry A Day; Chanita Hughes-Halbert; Evan M Graboyes Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-12-01 Impact factor: 6.223
Authors: T Vanderhaegen; A Pierache; G Mortuaire; B Rysman; R Nicot; D Chevalier; F Mouawad Journal: Eur Ann Otorhinolaryngol Head Neck Dis Date: 2022-04-22 Impact factor: 2.665
Authors: Rosanne C Schoonbeek; Julius de Vries; Linda Bras; Grigory Sidorenkov; Boudewijn E C Plaat; Max J H Witjes; Bernard F A M van der Laan; Johanna G M van den Hoek; Boukje A C van Dijk; Johannes A Langendijk; György B Halmos Journal: Eur J Cancer Care (Engl) Date: 2022-04-19 Impact factor: 2.328
Authors: José Luis Lopez-Cedrún; Ana Otero-Rico; Inés Vázquez-Mahía; Juan Seoane; Lucía García-Caballero; Juan Manuel Seoane-Romero; Pablo Varela-Centelles Journal: PLoS One Date: 2019-10-25 Impact factor: 3.240
Authors: Rosanne C Schoonbeek; Suzanne Festen; Roza Rashid; Boukje A C van Dijk; György B Halmos; Lilly-Ann van der Velden Journal: Otolaryngol Head Neck Surg Date: 2022-01-19 Impact factor: 5.591